Your AI-Trained Oncology Knowledge Connection!

Lower-Risk Myelodysplastic Syndromes (LR-MDS): Highlights from EHA 2024 : Episode 9

Opinion

Video

July 29, 2024

Dr.'s Cluzeau and Komrokji on Utilization Patterns of luspatercept in LR-MDS EHA 2024 Data

Author(s):

Guillermo Garcia-Manero, MD,Rami Komrokji, MD

Medical professionals examine the utilization patterns of luspatercept in lower-risk myelodysplastic syndromes (LR-MDS) and their impact on patient treatment strategies.

EP: 1.Navigating Myelodysplastic Syndromes: Updates to WHO & ICC Guidelines, IPSS-M, and Risk Stratification

EP: 2.Dr Oliva on Addressing Challenges in Treating Lower-Risk MDS 

EP: 3.Frontline Therapy for Lower-Risk MDS: Global Perspectives and Treatment Selection Strategies

EP: 4.Review of the COMMANDS Trial

EP: 5.Perceptions of the EHA 2024 Full Analysis of the COMMANDs Trial

EP: 6.Clinical Implications of COMMANDS Trial in Clinical Practice

EP: 7.Treatment Decision-Making Based on the COMMANDS Trials

EP: 8.Exploring Biomarker Analysis, Real-World Data, and Quality of Life in LR-MDS: Insights from EHA 2024

Now Viewing

EP: 9.Dr.'s Cluzeau and Komrokji on Utilization Patterns of luspatercept in LR-MDS EHA 2024 Data

EP: 10.Safety Profile of Available Frontline Treatments LR-MDS

EP: 11.1L treatment of lower-risk MDS beyond luspatercept

EP: 12.Sequencing Second-Line Treatments for LR-MDS

EP: 13.Perspectives of IMerge Study

EP: 14.Real-World Evidence and Emerging Therapies in Lower-Risk MDS: Insights from EHA 2024

EP: 15.EHA 2024 Future Directions in Lower-Risk MDS Treatment: Emerging Data, Approvals, and Guideline Updates

EP: 16.Final Thoughts on EHA 2024 Data for Lower-Risk MDS

Dr. Thomas Cluzeau: Utilization patterns of luspatercept in LR-MDS

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity

Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity

Video

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Apr 8th 2025 - May 14th 2025

online-activity

Latest Conference Coverage

Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

Application of Real-World Evidence in Selecting CAR T in R/R MM

Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Following ASCT

Apalutamide Boosts 24-Month OS in Real-World Population With Metastatic Castration-Sensitive Prostate Cancer

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Dr.'s Cluzeau and Komrokji on Utilization Patterns of luspatercept in LR-MDS EHA 2024 Data

EP: 1.Navigating Myelodysplastic Syndromes: Updates to WHO & ICC Guidelines, IPSS-M, and Risk Stratification

EP: 2.Dr Oliva on Addressing Challenges in Treating Lower-Risk MDS

EP: 3.Frontline Therapy for Lower-Risk MDS: Global Perspectives and Treatment Selection Strategies

EP: 4.Review of the COMMANDS Trial

EP: 5.Perceptions of the EHA 2024 Full Analysis of the COMMANDs Trial

EP: 6.Clinical Implications of COMMANDS Trial in Clinical Practice

EP: 7.Treatment Decision-Making Based on the COMMANDS Trials

EP: 8.Exploring Biomarker Analysis, Real-World Data, and Quality of Life in LR-MDS: Insights from EHA 2024

EP: 9.Dr.'s Cluzeau and Komrokji on Utilization Patterns of luspatercept in LR-MDS EHA 2024 Data

EP: 10.Safety Profile of Available Frontline Treatments LR-MDS

EP: 11.1L treatment of lower-risk MDS beyond luspatercept

EP: 12.Sequencing Second-Line Treatments for LR-MDS

EP: 13.Perspectives of IMerge Study

EP: 14.Real-World Evidence and Emerging Therapies in Lower-Risk MDS: Insights from EHA 2024

EP: 15.EHA 2024 Future Directions in Lower-Risk MDS Treatment: Emerging Data, Approvals, and Guideline Updates

EP: 16.Final Thoughts on EHA 2024 Data for Lower-Risk MDS

Newsletter

Latest CME

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arkansas

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arkansas

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arkansas

Latest Conference Coverage